Floatz logo

Irinotecan

Liver And Intrahepatic Bile Duct Neoplasm

Tehran University of Medical SciencesSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Liver And Intrahepatic Bile Duct Neoplasm cohort.

Asset / SponsorPhaseRating
Chlorhexidine
Changhua Christian Hospital
Phase 4BB
Albumin Aggregated
Sirtex Medical
Phase 4BB
Talaporfin
Light Sciences Oncology
Phase 3BB
Xaliplatin
Shanghai Zhongshan Hospital
Phase 4BB
Sorafenib
Sichuan Cancer Hospital and Research Institute
Phase 3BB

View all 49 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerActive
BBB
Indicative · Phase 4
78 / 100
View asset →
exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →